Clinical trials: Cirrhosis
Cirrhosis
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation.
- Trial name
- Ant-TIPS (NCT07889726)
- Testing
- TIPS, Standard of Care (SOC)
- Where
- 8 sites in France
- Volunteers
- 266 people
- Sponsor
- University Hospital, Toulouse
Heart Failure, Liver Fibrosis
Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
Magnetic resonance elastography is a novel non-invasive MRI technique to obtain stiffness of soft tissues such as liver, heart, kidneys, etc.
- Conditions
- Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
- Trial name
- MRE (NCT01757730)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Arunark Kolipaka
Primary Biliary Cirrhosis
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver…
- Trial name
- ELATIVE (NCT04526665)
- Testing
- Elafibranor 80mg
- Where
- 115 sites in United States, Argentina and 12 more
- Volunteers
- 161 people
- Sponsor
- Ipsen
Hepatitis B
Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia
The goal of this observational study is to study models of care for decentralized hepatitis B treatment in Ethiopia. Three different models of decentralized HBV care (standard model, simplified model, test-and-treat model) will…
- Trial name
- NCT06586983
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Ethiopia
- Volunteers
- 4,500 people
- Sponsor
- Oslo University Hospital
HCC - Hepatocellular Carcinoma, Cirrhosis
Non-invasive Assessment for Outcome Prediction in Patients With Hepatocellular Carcinoma
This is a single-centre, prospective cohort study. Consecutive patients with compensated liver disease and hepatocellular carcinoma (HCC) for curative-intent treatment will be invited to this study.
- Trial name
- NCT07036874
- Testing
- transient elastography and oesophagogastroduodenoscopy
- Where
- Hong Kong
- Volunteers
- 159 people
- Sponsor
- Chinese University of Hong Kong
Cirrhosis, Advanced Chronic Liver Disease
Natural History of Advanced Chronic Liver Diseases
This is a retrospective-prospective registry cohort study. Patients with advanced chronic liver disease (ACLD) will be prospectively invited to this study. The study follow-up duration will be 10 years.
- Trial name
- NCT07042308
- Testing
- Transient elastography
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Trial name
- ENDO-MASH (NCT07877272)
- Testing
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Muenster
Sexual Dysfunction in Patients With Cirrhosis Awaiting Liver Transplantation
Sexual Dysfunction in Cirrhosis
The prevalence of erectile dysfunction (ED) is about 10% in the general population, but increases with age, ranging from 9.1% in men 40-49 years to 55% in men >70.
- Trial name
- SEDYC (NCT05428267)
- Testing
- questionnaire, blood collection
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Decompensated Cirrhosis
Risk Stratification for Adverse Events in End-Stage Liver Disease
Study Goal The goal of this multicenter, prospective observational cohort study is to develop and validate a multimodal predictive model that integrates portal hypertension, inflammation, and liver function indicators to predict…
- Trial name
- D-TECT (NCT07880678)
- Testing
- Routine Clinical Care with Biospecimen Collection and Free MRE Testing
- Volunteers
- 2,235 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment.
- Conditions
- Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms
- Trial name
- NCT05286814
- Testing
- Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Cirrhosis
A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram
The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for…
- Trial name
- ADVANCE (NCT05782283)
- Testing
- ACE (AI-Cirrhosis-ECG) 2.0
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Mayo Clinic
Primary Biliary Cholangitis (PBC)
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
The present phase 1b/2 randomised, double-blind, placebo-controlled, two-part study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of two dose levels of golexanolone…
- Trial name
- NCT07304843
- Testing
- golexanolone
- Where
- 38 sites in Germany, Greece and 6 more
- Volunteers
- 207 people
- Sponsor
- Umecrine Cognition AB
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT07553663
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corcept Therapeutics
Liver Cirrhosis, Sleep Disturbance
Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis
This study will evaluate the efficacy and safety of daridorexant, a dual orexin receptor antagonist, in adults with liver cirrhosis and sleep disturbance, including participants with or without covert hepatic encephalopathy.
- Conditions
- Liver Cirrhosis, Sleep Disturbance, Hepatic Encephalopathy
- Trial name
- NCT07830303
- Testing
- Daridorexant
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Wang Fengmei
Liver Cirrhosis, Hepatic Cell Carcinoma
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols.
- Conditions
- Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
- Trial name
- NCT06265272
- Testing
- Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Liver Cirrhosis
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- Trial name
- NCT07325526
- Testing
- BI 3802876
- Where
- 27 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Liver Cirrhosis, Hepatic Encephalopathy (HE)
Equivalence of Electronic vs Paper-based PHES in Diagnosing Hepatic Encephalopathy
The goal of this clinical trial is to learn if an electronic version of the Psychometric Hepatic Encephalopathy Score (PHES) works as well as the standard paper version to diagnose minimal hepatic encephalopathy (MHE) in adults…
- Conditions
- Liver Cirrhosis, Hepatic Encephalopathy (HE), Minimal Hepatic Encephalopathy
- Trial name
- NCT07874204
- Testing
- Paper-based PHES, Electronic PHES
- Volunteers
- 80 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sarcopenia, Liver Cirrhosis
Microbiome and Sarcopenia in Patients With Liver Cirrhosis
Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70% of cirrhotic patients.
- Trial name
- NCT03080129
- Testing
- Fresubin energy
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Liver Cirrhosis
AGRA Before and After Liver Transplantation
The immune system is impaired in liver cirrhotic patients, which is associated with a high risk for bacterial infections and worse outcome.
- Trial name
- NCT03446521
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Medical University of Graz